Skip to content

The effects of dietary nitrate supplementation on metabolic efficiency in patients with COPD

The effects of dietary nitrate supplementation on metabolic efficiency in patients with COPD - Nitrate supplementation in COPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON44154
Enrollment
20
Registered
2014-08-04
Start date
2015-09-25
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Each subject will consume (in a randomized fashion) both the intervention beverage (NaNO3 solution: 7x ~140 mL
7x ~8 mmol NO3-1)) and the placebo (NaCl solution: 7x ~140 mL), separated by a 1 wk washout period.

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. 2) Peak VO2 / peak load > 10 ml/min/W, as a indication for metabolic inefficiency, determined using CPET data available from the assessment.

Exclusion criteria

Exclusion criteria: - Sodium intake limitation - Long-term oxygen therapy, because of the methodology that is used to measure oxygen uptake and ventilation - Severe renal impairment (GFR

Design outcomes

Primary

MeasureTime frame
The primary parameter is metabolic efficiency during submaximal cycle ergometry tests (before and after 7 days of ingestion of both NaNO3 solution and NaCl placebo). Metabolic efficiency will be calculated with the following equation: Metabolic efficiency = (load (W) of exercise * 0.01433 (kcal*min-1) / (energy expenditure during exercise * REE)(kcal*min-1)*100%

Secondary

MeasureTime frame
Secondary parameters are bloodpressure, dyspnea, cycle endurance time, Oxygen uptake during rest and exercise, body temperature, blood markers (e.g. lactate, IFABP as a marker for intestinal damage and cardiac troponin as a marker for myocardial injury) . These parameters will be measured at 4 times (before and after 7 days of ingestion of both NaNO3 solution and NaCl placebo).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)